Oncotelic Therapeutics Advances AI and Robotics Platform Toward Commercial Deployment

Oncotelic Therapeutics (OTCQB: OTLC) has reported continued progress on its proprietary AI platform and robotics integration as the company nears initial commercial deployment. The clinical-stage biotechnology company has integrated approximately 28 million scientific abstracts into its PDAOAI platform and combined it with robotics developed alongside TechForce Robotics, enabling real-time, automated workflows designed to improve efficiency and support compliance in pharmaceutical development and manufacturing. This advancement marks a significant step toward leveraging artificial intelligence and automation to accelerate drug development processes.

The PDAOAI platform, which serves as the backbone of Oncotelic's AI capabilities, is designed to support research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. By incorporating such a vast repository of scientific literature, the platform can provide insights that were previously unattainable through manual analysis. The integration with robotics from TechForce Robotics further enhances the platform's utility by automating workflows, thereby reducing human error and increasing throughput.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company's mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform to support its research and development efforts.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic's position in oncology and rare disease therapeutics.

The implications of this announcement are multifaceted. The commercial deployment of an AI and robotics platform in pharmaceutical development could significantly reduce the time and cost associated with bringing new drugs to market. By automating workflows and integrating vast amounts of scientific data, the platform may help identify novel biomarkers and therapeutic targets more efficiently. Additionally, the enhanced compliance capabilities could streamline regulatory submissions and approvals.

For more information on Oncotelic Therapeutics, visit the company's newsroom at https://ibn.fm/OTLC. The full press release can be accessed at https://ibn.fm/2uitp.